Skip to main content

Advertisement

SpringerLink
Log in

How Do I Follow Patients With Early Breast Cancer After Completing Adjuvant Therapy

  • Breast Cancer (CI Falkson, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

With improvements in the detection and treatment of breast cancer, more women are surviving after diagnosis. Patients who complete adjuvant therapy require ongoing follow-up to manage toxicities, to detect recurrences early, and to provide ongoing physical and psychosocial support. Routine surveillance should be implemented, with attention to educating patients about symptoms of recurrence, such as weight loss, cough, and bone pain. An intensive surveillance strategy with the routine use of laboratory and radiographic studies does not improve outcomes and raises the cost of follow-up. Patients should have annual mammograms in conjunction with physical exam and history at appropriate intervals that increase the farther out patients are from treatment. Attention also should be focused on other routine health maintenance and cancer screening, such as colonoscopy, gynecologic examinations, and bone health/DEXA scans. In the early posttreatment period, medical oncologists are best equipped to follow these patients. However, as women live longer after a breast cancer diagnosis and treatment, transitioning care to a primary care physician or nurse practitioner is appropriate, provided these practitioners are educated about late treatment effects and managing side effects of treatment, which may continue as long as a decade. A multidisciplinary follow-up strategy with excellent communication between providers can ensure safe, convenient, and quality care to the growing population of breast cancer survivors. As the treatment of breast cancer evolves into personalized strategies based on the biologic characteristics of individual tumors, future studies will be needed to determine if a single surveillance strategy is sufficient or if individualized surveillance based on risk can improve outcomes and costs of long-term follow-up care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. This article provides the most up-to-date cancer statistics for the United States.

    Article  PubMed  Google Scholar 

  2. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41. This article provides the most up-to-date data and statistics on cancer treament and survivorship.

    Article  PubMed  Google Scholar 

  3. Rojas M, Telaro E, Russo A, Fossati R, Confalonieri C, Liberati A. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005;25(1):CD001768. This review, initially published in 2000 but reprinted in 2012, provides clear evidence that intensive surveillance strategies offer no improvement in overall survival or disease-free survival compared with limited surveillance.

  4. Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006;24:5091–7.

    Article  PubMed  Google Scholar 

  5. Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:961–5. This article provides the most recently updated guidelines for breast cancer surveillance of the American Society of Clinical Oncology.

    Article  CAS  PubMed  Google Scholar 

  6. Network NCC. NCCN Clinical Practice Guidelines Invasive Breast Cancer. [accessed August 6, 2013].

  7. Montgomery DA, Krupa K, Cooke TG. Alternative methods of follow up in breast cancer: a systematic review of the literature. Br J Cancer. 2007;96:1625–32.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Gulliford T, Opomu M, Wilson E, Hanham I, Epstein R. Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study. BMJ. 1997;314:174–7.

    Article  CAS  PubMed  Google Scholar 

  9. Grunfeld E, Mant D, Yudkin P, et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ. 1996;313:665–9.

    Article  CAS  PubMed  Google Scholar 

  10. Grunfeld E, Fitzpatrick R, Mant D, et al. Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: results from a randomized controlled trial. Br J Gen Pract. 1999;49:705.

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Grunfeld E, Levine MN, Julian JA, et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol. 2006;24:848–55.

    Article  PubMed  Google Scholar 

  12. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16. This trial provides evidence that 10 years of tamoxifen offers additional mortality and recurrence benefits compared to 5 years of tamoxifen. The results will likely be practice-changing and suggest that breast cancer survivors will be on therapy longer than in the past.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst. 2005;97:1262–71.

    Article  CAS  PubMed  Google Scholar 

  14. Khatcheressian J, Swainey C. Breast cancer follow-up in the adjuvant setting. Curr Oncol Rep. 2008;10:38–46.

    Article  PubMed  Google Scholar 

  15. Donnelly P, Hiller L, Bathers S, Bowden S, Coleman R. Questioning specialists’ attitudes to breast cancer follow-up in primary care. Ann Oncol. 2007;18:1467–76.

    Article  CAS  PubMed  Google Scholar 

  16. Roorda C, Berendsen AJ, Haverkamp M, van der Meer K, de Bock GH. Discharge of breast cancer patients to primary care at the end of hospital follow-up: a cross-sectional survey. Eur J Cancer. 2013;49:1836–44. This cross-sectional survey evaluated patient, PCP and specialist experiences and views regarding transfer of follow-up to the primary care setting. The results support PCP follow-up of patients, but with detailed surviorship care plans and adequate clinical and administrative training for PCPs.

    Article  PubMed  Google Scholar 

  17. Mao JJ, Bowman MA, Stricker CT, et al. Delivery of survivorship care by primary care physicians: the perspective of breast cancer patients. J Clin Oncol. 2009;27:933–8.

    Article  PubMed  Google Scholar 

  18. Mallinger JB, Griggs JJ, Shields CG. Patient-centered care and breast cancer survivors’ satisfaction with information. Patient Educ Couns. 2005;57:342–9.

    Article  PubMed  Google Scholar 

  19. Salminen E, Vire J, Poussa T, Knifsund S. Unmet needs in information flow between breast cancer patients, their spouses, and physicians. Support Care Cancer. 2004;12:663–8.

    CAS  PubMed  Google Scholar 

  20. Hodgkinson K, Butow P, Hunt GE, Pendlebury S, Hobbs KM, Wain G. Breast cancer survivors’ supportive care needs 2–10 years after diagnosis. Support Care Cancer. 2007;15:515–23.

    Article  PubMed  Google Scholar 

  21. Ghezzi PP, Magnanini SS, Rinaldini MM, et al. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA. 1994;271:1587–92.

    Google Scholar 

  22. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994;271:1593–7.

    Article  CAS  PubMed  Google Scholar 

  23. Palli D, Russo A, Saieva C, et al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA. 1999;281:1586.

    Article  CAS  PubMed  Google Scholar 

  24. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005;23:2716–25.

    Article  PubMed  Google Scholar 

  25. de Bock GH, Bonnema J, van der Hage J, Kievit J, van de Velde CJ. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. J Clin Oncol. 2004;22:4010–8.

    Article  PubMed  Google Scholar 

  26. Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol. 2007;25:1074–81.

    Article  PubMed  Google Scholar 

  27. Collins RF, Bekker HL, Dodwell DJ. Follow-up care of patients treated for breast cancer: a structured review. Cancer Treat Rev. 2004;30:19–35.

    Article  PubMed  Google Scholar 

  28. Holli K, Saaristo R, Isola J, Hyoty M, Hakama M. Effect of radiotherapy on the interpretation of routine follow-up mammography after conservative breast surgery: a randomized study. Br J Cancer. 1998;78:542–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Grunfeld E, Noorani H, McGahan L, et al. Surveillance mammography after treatment of primary breast cancer: a systematic review. Breast. 2002;11:228–35.

    Article  CAS  PubMed  Google Scholar 

  30. Grunfeld E, Dhesy-Thind S, Levine M. Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). Can Med Assoc J. 2005;172:1319–20.

    Article  Google Scholar 

  31. Mandelblatt JS, Lawrence WF, Cullen J, et al. Patterns of care in early-stage breast cancer survivors in the first year after cessation of active treatment. J Clin Oncol. 2006;24:77–84.

    Article  PubMed  Google Scholar 

  32. Lash TL, Silliman RA. Medical surveillance after breast cancer diagnosis. Med Care. 2001;39:945–55.

    Article  CAS  PubMed  Google Scholar 

  33. Schapira MM, McAuliffe TL, Nattinger AB. Underutilization of mammography in older breast cancer survivors. Med Care. 2000;38:281–9.

    Article  CAS  PubMed  Google Scholar 

  34. Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol. 2006;24:85–94.

    Article  PubMed  Google Scholar 

  35. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23:8469–76.

    Article  PubMed  Google Scholar 

  36. Leach MO, Boggis C, Dixon A, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365:1769–78.

    Article  CAS  PubMed  Google Scholar 

  37. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007;356:1295–303.

    Article  CAS  PubMed  Google Scholar 

  38. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89.

    Article  PubMed  Google Scholar 

  39. Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010;7:18–27.

    Article  PubMed  Google Scholar 

  40. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105–12.

    Article  CAS  PubMed  Google Scholar 

  41. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.

    Article  CAS  PubMed  Google Scholar 

  42. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem. 2006;52:345–51.

    Article  CAS  PubMed  Google Scholar 

  43. Jäger W, Krdmer S, Lang N. 4 Disseminated breast cancer: does early treatment prolong survival without symptoms? Breast. 1995;4:65.

    Article  Google Scholar 

  44. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by ‘early’ salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer. 1997;76:1106–11.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Nicolini A, Carpi A, Michelassi C, et al. “Tumour marker guided” salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. Biomed Pharmacother. 2003;57:452–9.

    Article  CAS  PubMed  Google Scholar 

  46. Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik S. Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial. Cancer Chemother Pharmacol. 1994;35:80–3.

    Article  CAS  PubMed  Google Scholar 

  47. Blamey RW. Guidelines on endocrine therapy of breast cancer EUSOMA. Eur J Cancer. 2002;38:615–34.

    Article  CAS  PubMed  Google Scholar 

  48. Pestalozzi BC, Luporsi-Gely E, Jost LM, Bergh J. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol. 2005;16 Suppl 1:i7–9.

    Article  PubMed  Google Scholar 

  49. Thomas DB, Gao DL, Ray RM, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst. 2002;94:1445–57.

    Article  PubMed  Google Scholar 

  50. De Jong N, Candel M, Schouten H, Abu-Saad HH, Courtens A. Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol. 2004;15:896–905.

    Article  PubMed  Google Scholar 

  51. Network NCC. NCCN Guidelines Version 1.2013: Survivorship Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf [accessed August 7, 2013]. This website outlines the NCCN recommendations for survivorship care and is an excellent clinical resource for guiding follow-up and management of cancer treatment side effects.

  52. Network NCC. NCCN Clinical Practice Guidelines in Oncology: Cancer-related fatigue. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf [accessed August 7, 2013]. This website details the NCCN recommendations for managing cancer-related fatigue and is an excellent clinical resource.

  53. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;135:335–46.

    Article  CAS  PubMed  Google Scholar 

  54. Schmitz KH, Prosnitz RG, Schwartz AL, Carver JR. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer. 2012;118:2270–6.

    Article  PubMed  Google Scholar 

  55. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869–79.

    Article  CAS  PubMed  Google Scholar 

  56. Carver JR. Management of trastuzumab-related cardiac dysfunction. Prog Cardiovasc Dis. 2010;53:130–9. This article provides an excellent summary of the diagnosis and management of trastuzumab-related cardiac dysfunction.

    Article  CAS  PubMed  Google Scholar 

  57. Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol. 2012;30:718–21. This article provides long-term follow-up of the MA.17 trial and provides evidence that 5 years of letrozole after 5 years of tamoxifen offers additional survival benefit and recurrence risk reduction.

    Article  CAS  PubMed  Google Scholar 

  58. Gray R, Rea D, Handley K. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31(suppl):abstr5. This study is the U.S. equivalent to ATLAS and shows that there is survival and risk reduction benefit to continuing tamoxifen for 10 years versus 5. The results are likely to change practice recommendations.

  59. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8:119–27.

    Article  CAS  PubMed  Google Scholar 

  60. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol. 2006;24:5305–12.

    Article  CAS  PubMed  Google Scholar 

  61. Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone. 2007;41:346–52.

    Article  CAS  PubMed  Google Scholar 

  62. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002;20:1128–43.

    Article  PubMed  Google Scholar 

  63. Connor AE, Baumgartner RN, Pinkston C, Baumgartner KB. Obesity and risk of breast cancer mortality in Hispanic and non-Hispanic white women: the New Mexico Women’s Health Study. J Women’s Health (Larchmt). 2013;22:368–77. This is one study that shows a survival benefit to maintaining a healthy body weight after breast cancer treatment.

    Article  Google Scholar 

  64. Sparano JA, Wang M, Zhao F, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. 2012;118:5937–46. This trial evaluated the relation between BMI and outcomes in 3 adjuvant chemotherapy ECOG trials (E1199, E5188, E3189) and found that obesity was associated with inferior outcomes in patients with HR+ operable breast cancer.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 2005;293:2479–86.

    Article  CAS  PubMed  Google Scholar 

  66. Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst. 2006;98:1767–76.

    Article  PubMed  Google Scholar 

  67. Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol. 2007;25:2345–51.

    Article  PubMed Central  PubMed  Google Scholar 

  68. Pierce JP, Natarajan L, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trial. JAMA. 2007;298:289–98.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Schmitz KH, Ahmed RL, Troxel AB, et al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA. 2010;304:2699–705. This clinical trial showed that weight lifting after axillary lymph node ressection does not increase the risk of lymphedema, a feared complication of breast cancer surgery. Given the benefits of weight lifting, this is an important trial that has lifestyle implications for many breast cancer survivors.

    Article  CAS  PubMed  Google Scholar 

  70. Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. 2009;361:664–73.

    Article  CAS  PubMed  Google Scholar 

  71. Ganmaa D, Sato A. The possible role of female sex hormones in milk from pregnant cows in the development of breast, ovarian and corpus uteri cancers. Med Hypotheses. 2005;65:1028–37.

    Article  CAS  PubMed  Google Scholar 

  72. Pape-Zambito D, Roberts R, Kensinger R. Estrone and 17β-estradiol concentrations in pasteurized-homogenized milk and commercial dairy products. J Dairy Sci. 2010;93:2533–40.

    Article  CAS  PubMed  Google Scholar 

  73. Kroenke CH, Kwan ML, Sweeney C, Castillo A, Caan BJ. High- and low-fat dairy intake, recurrence, and mortality after breast cancer diagnosis. J Natl Cancer Inst. 2013;105:616–23.

    Article  CAS  PubMed  Google Scholar 

  74. Nechuta SJ, Caan BJ, Chen WY, et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr. 2012;96:123–32.

    Article  CAS  PubMed  Google Scholar 

  75. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13:R64.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of Interest

Jennifer M. Matro and Lori J. Goldstein declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA

    Jennifer M. Matro MD & Lori J. Goldstein MD

Authors
  1. Jennifer M. Matro MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lori J. Goldstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lori J. Goldstein MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matro, J.M., Goldstein, L.J. How Do I Follow Patients With Early Breast Cancer After Completing Adjuvant Therapy. Curr. Treat. Options in Oncol. 15, 63–78 (2014). https://doi.org/10.1007/s11864-013-0265-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-013-0265-1

Keywords

Search

Navigation